BMO Capital Initiates Coverage On Taysha Gene Therapies With Outperform Rating, Announces Price Target of $5
BMO Capital Initiates Coverage On Taysha Gene Therapies With Outperform Rating, Announces Price Target of $5
華美銀行資本發表研究報告，對taysha gene therapies股票進行跟蹤評級，並宣佈目標股價爲5美元。
BMO Capital analyst Keith Tapper initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating and announces Price Target of $5.
BMO Capital的分析師Keith Tapper開始覆蓋Taysha Gene Therapies (NASDAQ:TSHA)，並給出超越市場表現評級和5美元的目標價格。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。